|Intra Cellular Therapies Inc -- USA Stock|| |
USD 21.59 0.64 2.88%
Vice President of Drug Discovery
Dr. Lawrence P. Wennogle Ph.D. is Vice President Drug Discovery of IntraCellular Therapies Inc. For the past 33 years Dr. Wennogle was involved in research and development in the pharmaceutical industry aimed at the discovery of novel pharmaceutical entities for human diseases. He was a Staff Scientist and Principal Research Fellow at CibaGeigy and Novartis Pharmaceutical Corporationrationration for 19 years where he led drug discovery programs for CNS disorders cardiovascular diseases diabetes and inflammation
Age: 65 President Since 2014 Ph.D
Wennogle received his B.A. from Ithaca College and his Ph.D. in Biochemistry from the University of Colorado, Boulder. He then completed two postdoctoral positions, one at the University of Colorado and the second at the Pasteur Institute in Paris, France, working under JeanPierre Changeux on the structurefunction of the nicotinic acetylcholine receptor.
The company has return on total asset (ROA)
of (14.94) %
which means that it has lost $14.94 on every $100 spent on asset. This is way below average. Similarly, it shows return on stockholders equity (ROE)
of (23.56) %
meaning that it created substantial loss on money invested by shareholders.
Intra-Cellular Therapies, Inc., a biopharmaceutical company, engages in developing novel drugs for the treatment of neuropsychiatric and neurodegenerative diseases. Intra-Cellular Therapies, Inc. is headquartered in New York, New York. Intra Cellular operates under Biotechnology classification in USA and traded on NASDAQ. It employs 49 people.Intra Cellular Therapies Inc (ITCI) is traded on NASDAQ in USA. It is located in NEW YORK, U.S.A and employs 49 people. Intra Cellular is listed under Pharmaceutical Products category by Fama And French industry classification.